Fundamental Analysis Stories

VBLT
  over six months ago at Macroaxis 
By Rifka Kats
Vascular Biogen Ord is scheduled to announce its earnings tomorrow. Healthcare space may be getting hot again, let's check if Vascular Biogen Ord is sending any bullish signals to investors. I will address the reasons this entity was abused by private investors resulted from the current market uncertainty. This firm follows the market closely. We can now break down Vascular as a potential investment option for your portfolios.
OEG
  over six months ago at Macroaxis 
By Ellen Johnson
Orbital Energy Group is scheduled to announce its earnings tomorrow. As some conservatives are trying to avoid utilities space, we'll digest Orbital Energy Group a little further and explain its current market possibilities. We will cover the possibilities of making Orbital Energy into a steady grower in September. The entity almost mirrors the market. We can now discuss Orbital as a potential investment option for your portfolios.
FLGC
  over six months ago at Macroaxis 
By Vlad Skutelnik
Despite somewhat unsteady technical and fundamental indicators, FLORA GROWTH sustained solid returns over the last few months and may actually be approaching a breakup point. FLORA GROWTH current odds of financial turmoil is under 45 percent. Will investors continue to be optimistic, or should we expect a sell-off?
DSEY
  over six months ago at Macroaxis 
By Vlad Skutelnik
If you have been following Diversey you may be considering acquiring. Let's check if strong technical and fundamental indicators will continue to push the price to rise for Diversey Holdings' investors. Will investors continue to hold, or should we expect a sell-off?
DDS
  over six months ago at Macroaxis 
By Raphi Shpitalnik
Dillards is scheduled to announce its earnings today. The next earnings report is expected on the 11th of November 2021. The stock is currently experiencing an unusual volatility. As some conservatives are trying to avoid consumer cyclical space, we'll sum up Dillards a little further and explain its current market possibilities. We will analyze why Dillards investors may still consider a stake in the business. Will retail investors continue to hold, or should we expect a sell-off?
RDCM
  over six months ago at Macroaxis 
By Raphi Shpitalnik
If you are looking to grow your portfolio over time, you may want to summarize all of the essential fundamental indicators of your selected equities before buying their shares. In this article, we will summarize Radcom. We will evaluate if Radcom shares are reasonably priced going into September. Will stakeholders continue to hold, or should we expect a sell-off?
ATC
  over six months ago at Macroaxis 
By Ellen Johnson
Atotech Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to increase significantly based on the last few years of reporting. The past year's Earnings Before Interest Taxes and Depreciation Amortization EBITDA were at 369.7 Million. The current year EBITDA Margin is expected to grow to 0.31, whereas Earnings before Tax are forecasted to decline to (231 M). Atotech Limited is scheduled to announce its earnings today. The next earnings report is expected on the 4th of February 2022. As some conservatives are trying to avoid technology space, we'll go over Atotech Limited a little further and explain its current market possibilities. Atotech Limited moves indifferently to market moves. We can now analyze Atotech as a potential investment option for your portfolios.
CLSN
  over six months ago at Macroaxis 
By Ellen Johnson
Celsion Corp Market Capitalization is quite stable at the moment as compared to the past year. The company's current value of Market Capitalization is estimated at 38.7 Million. Tangible Asset Value is expected to rise to about 39.9 M this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (23 M). Celsion Corp is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 13th of August 2021. As some conservatives are trying to avoid healthcare space, we'll outline Celsion Corp a little further and explain its current market possibilities. We will look into reasons why it is still very possible for the company to generate above-average returns. Celsion Corp moves indifferently to market moves. We can now inspect Celsion as a potential investment option for your portfolios.
NGD
  over six months ago at Macroaxis 
By Vlad Skutelnik
New Gold Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease significantly based on the last few years of reporting. The past year's Earnings Before Interest Taxes and Depreciation Amortization EBITDA were at 198.8 Million. The current year Average Equity is expected to grow to about 1.3 B, whereas Asset Turnover is forecasted to decline to 0.26. If you are looking to grow your portfolio over time, you may want to digest all of the essential technical and fundamental indicators of your selected equities before buying their shares. In this article, we will digest New Gold. New Gold odds of distress is under 44 percent. Will New Gold shareholders continue to purchase in September?
CBAY
  over six months ago at Macroaxis 
By Gabriel Shpitalnik
Cymabay Therapeutics Net Cash Flow from Investing is fairly stable at the moment as compared to the past year. Cymabay Therapeutics reported Net Cash Flow from Investing of 47.96 Million in 2020. Net Cash Flow Investment Acquisitions and Disposals is likely to rise to about 51.8 M in 2021, whereas Average Assets are likely to drop slightly above 143.2 M in 2021. Cymabay Therapeutics is scheduled to announce its earnings tomorrow. The next earnings report is expected on the 4th of November 2021. While some of us are getting worried about healthcare space, it is reasonable to break down Cymabay Therapeutics using its current fundamental data. We will analyze why it could be a much better year for Cymabay Therapeutics shareholders. This firm current probability of bankruptcy is under 3 percent. Will investors continue to be optimistic, or should we expect a sell-off?